Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12769572 | 1.00 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12769562 | 0.85 | — | — | |
| SCHEMBL12049888 | 0.85 | — | — | |
| SCHEMBL19861752 | 0.83 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12049889 | 0.83 | DUT (0.45) | SLC29A1 | |
| SCHEMBL12769566 | 0.83 | DUT (0.45) | SLC29A1 | |
| SCHEMBL10072871 | 0.83 | LMNA (0.37) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL20227071 | 0.83 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL25401632 | 0.79 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL26288124 | 0.79 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071567-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | LMNA 3086/4885THRB 4128/4885MTOR 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.